Henry Johnson

Dr. Johnson joined the team as Vice President of Chemistry in June of 2022 and brings to Tempest more than 18 years of experience contributing to the discovery and development of novel chemical entities targeting the unmet medical needs of patients. He recently served as Executive Director of Chemistry at BridGene Biosciences, a proteomics-focused biotechnology company, and as a Director at Kezar Life Sciences where he was a primary contributor to the discovery and development of the company’s clinical assets Zetomipzomib (KZR-616) and KZR-261. Prior to Kezar he held positions of increasing responsibility within the industry at Amgen/Onyx Pharmaceuticals and Exelixis, contributing his expertise to several programs that advanced into the clinic including the approved therapy MINNEBRO®. He has authored over 40 scientific publications and patents spanning diverse therapeutic areas.

Dr. Johnson earned a Ph.D. in Chemistry from the University of Utah and a B.S. in Biochemistry from California Polytechnic State University, San Luis Obispo.